慢性自发性荨麻疹的临床评估体系

doi:10.35541/cjd.20210379

Abstract

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） greatly affects the quality of life of patients. Currently, no sensitive and convenient biomarkers are available to assess the severity of CSU and efficacy of drug therapies. It is particularly important to apply patient-reported outcome assessment tools with good reliability and validity in daily management of CSU, such as urticaria activity score, urticaria control test and chronic urticaria quality of life questionnaire. This review outlines the existing CSU assessment tools, analyzes their strengths, limitations and clinical application, aiming to establish a CSU clinical scoring system, and to facilitate personalized treatment and efficacy evaluation.

Key words: Urticaria, Quality of life, Health status indicators, Disease activity, Disease control

Yu Miao, Chen Yudi, Liu Bo, Song Xiaoting, Liao Shuanglu, Luan Tingting, Zhao Zuotao. Scoring systems for chronic spontaneous urticaria in clinical research and practice[J]. Chinese Journal of Dermatology, 2021, 54(12): 1117-1121.doi:10.35541/cjd.20210379

References ［30］

［1］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［2］	Zhong H, Song Z, Chen W, et al. Chronic urticaria in Chinese population: a hospital⁃based multicenter epidemiological study［J］. Allergy, 2014,69（3）:359⁃364. doi: 10.1111/all.12338.
［3］	Maurer M, Abuzakouk M, Bérard F, et al. The burden of chronic spontaneous urticaria is substantial: real⁃world evidence from ASSURE⁃CSU［J］. Allergy, 2017,72（12）:2005⁃2016. doi: 10. 1111/all.13209.
［4］	Chu CY, Cho YT, Jiang JH, et al. Patients with chronic urticaria have a higher risk of psychiatric disorders: a population⁃based study［J］. Br J Dermatol, 2020,182（2）:335⁃341. doi: 10.1111/bjd.18240.
［5］	陈玉迪, 耿鹏, 赵嘉惠, 等. 慢性自发性荨麻疹:奥马珠单抗治疗作用机制与疗效评估［J］. 中华皮肤科杂志, 2019,52（9）:652⁃655. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.014.
［6］	Chen YD, Maurer M, Yu M, et al. Addition of omalizumab to antihistamine treatment in chronic urticaria: a real⁃world study in China［J］. Ann Allergy Asthma Immunol, 2020,125（2）:217⁃219. doi: 10.1016/j.anai.2020.04.026.
［7］	Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both［J］. World Allergy Organ J, 2021,14（1）:100501. doi: 10.1016/j.waojou.2020.100501.
［8］	Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study［J］. Allergy, 2021,76（4）:1271⁃1273. doi: 10.1111/all.14686.
［9］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［10］	Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score⁃validity, reliability, and responsiveness［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1185⁃1190.e1. doi: 10.1016/j.jaip.2017.10.001.
［11］	de Montjoye L, Darrigade AS, Giménez⁃Arnau A, et al. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria［J］. Eur Ann Allergy Clin Immunol, 2021,53（2）:55⁃66. doi: 10.23822/EurAnnACI.1764⁃1489.132.
［12］	谷锋, 沈云良. 血清IL⁃31表达水平与慢性自发性荨麻疹患者病变严重程度、瘙痒程度和生活质量的相关性研究［J］. 中华全科医学, 2019,17（9）:1527⁃1529. doi: 10.16766/j.cnki.issn. 1674⁃4152.000988.
［13］	Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the angioedema activity score［J］. Allergy, 2013,68（9）:1185⁃1192. doi: 10.1111/all.12209.
［14］	Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient⁃reported outcome instrument for assessing urticaria control［J］. J Allergy Clin Immunol, 2014,133（5）:1365⁃1372,1372.e1⁃6. doi: 10.1016/ j.jaci.2013.12.1076.
［15］	于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证［J］. 中华皮肤科杂志, 2020,53（7）:533⁃538. doi: 10. 35541/cjd.20191190.
［16］	Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Validity, reliability and interpretability of the Thai version of the urticaria control test （UCT）［J］. Health Qual Life Outcomes, 2016,14:61. doi: 10.1186/s12955⁃016⁃0466⁃y.
［17］	Weller K, Donoso T, Magerl M, et al. Validation of the angioedema control test （AECT）⁃a patient⁃reported outcome instrument for assessing angioedema control［J］. J Allergy Clin Immunol Pract, 2020,8（6）:2050⁃2057.e4. doi: 10.1016/j.jaip. 2020.02.038.
［18］	朱海军, 庞雅男, 李芳芳, 等. 慢性荨麻疹患者生活质量评估及影响因素分析［J］. 中国中西医结合皮肤性病学杂志, 2020,19（6）:536⁃539.
［19］	Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x.
［20］	刘江波, 司爱丽, 邓蕾, 等. 慢性荨麻疹患者生活质量评估及皮肤病生活质量指数的因子分析和信度分析［J］. 中华皮肤科杂志, 2011,44（1）:47⁃49. doi: 10.3760/cma.j.issn.0412⁃4030. 2011.01.017.
［21］	Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index （DLQI）: further data［J］. Dermatology, 2015,230（1）:27⁃33. doi: 10.1159/000365390.
［22］	Balp MM, Khalil S, Tian H, et al. Burden of chronic urticaria relative to psoriasis in five European countries［J］. J Eur Acad Dermatol Venereol, 2018,32（2）:282⁃290. doi: 10.1111/jdv.14584.
［23］	Serra E, Campo C, Novák Z, et al. Efficacy and safety of bilastine in reducing pruritus in patients with chronic spontaneous urticaria and other skin diseases: an exploratory study［J］. J Dermatolog Treat, 2020,31（3）:270⁃278. doi: 10.1080/09546634. 2019.1590522.
［24］	Baiardini I, Braido F, Bindslev⁃Jensen C, et al. Recommendations for assessing patient⁃reported outcomes and health⁃related quality of life in patients with urticaria: a GA（2） LEN taskforce position paper［J］. Allergy, 2011,66（7）:840⁃844. doi: 10.1111/j.1398⁃9995.2011.02580.x.
［25］	Schut C, Dalgard FJ, Halvorsen JA, et al. Occurrence, chronicity and intensity of itch in a clinical consecutive sample of patients with skin diseases: a multi⁃centre study in 13 European countries［J］. Acta Derm Venereol, 2019,99（2）:146⁃151. doi: 10.2340/00015555⁃3040.
［26］	Baiardini I, Pasquali M, Braido F, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire （CU⁃QoL）［J］. Allergy, 2005,60（8）:1073⁃1078. doi: 10.1111/j.1398⁃9995.2005.00833.x.
［27］	于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091.
［28］	Baiardini I, Fasola S, Maurer M, et al. Minimal important difference of the chronic urticaria quality of life questionnaire （CU⁃Q2oL）［J］. Allergy, 2019,74（12）:2542⁃2544. doi: 10.1111/all.13939.
［29］	Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire［J］. Allergy, 2012,67（10）:1289⁃1298. doi: 10.1111/all.12007.
［30］	Weller K, Magerl M, Peveling⁃Oberhag A, et al. The angioedema quality of life questionnaire （AE⁃QoL） ⁃ assessment of sensitivity to change and minimal clinically important difference［J］. Allergy, 2016,71（8）:1203⁃1209. doi: 10.1111/all.12900.

[1]	Liu Qian, Li Guohong, Chen Bingwei. A survey on quality of life and its influencing factors among patients with non-melanoma skin cancers [J]. Chinese Journal of Dermatology, 2021, 54(9): 819-821.
[2]	Zhang Yu, Gao Yingxia, Gu Ningyan, Zhu Hong, Chen Jingjing, Hu Qingjie, Zhou Min, Duan Yuanyuan, Yao Xu. Clinical efficacy and safety of omalizumab in the treatment of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2021, 54(7): 582-585.
[3]	Liang Gaopeng, Song Zhiqiang. Role of immunoglobulin E autoantibodies in autoimmune skin diseases [J]. Chinese Journal of Dermatology, 2021, 54(6): 553-556.
[4]	Yan Huimin, Du Xiao, Meng Linghe, Weng Lishuo, Zeng Sanwu. Analysis of differences in gut microbiota in patients with chronic spontaneous urticaria by 16S rRNA high-throughput sequencing [J]. Chinese Journal of Dermatology, 2021, 54(12): 1071-1076.
[5]	Song Xiaoting, Liu Bo, Chen Yudi, Yu Miao, Liao Shuanglu, Luan Tingting, Zhao Zuotao. Efficacy and safety of omalizumab for treatment of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2021, 54(12): 1063-1070.
[6]	Zhao Zuotao. Diagnosis and treatment of chronic urticaria: current status and future prospects [J]. Chinese Journal of Dermatology, 2021, 54(12): 1105-1109.
[7]	Chen Qiquan, Song Zhiqiang. Treatment of chronic inducible urticaria [J]. Chinese Journal of Dermatology, 2021, 54(12): 1110-1113.
[8]	Centre for Urticaria Research, Chinese Society of Dermatology. Consensus on management of chronic urticaria using anti-immunoglobulin E therapy （omalizumab） [J]. Chinese Journal of Dermatology, 2021, 54(12): 1057-1062.
[9]	Liu Xin, Liu Nian, Chen Hongxiang. Diagnosis and treatment of contact urticaria [J]. Chinese Journal of Dermatology, 2021, 54(12): 1114-1117.
[10]	Wang Qianqiu, Du Fangzhi, Zhang Xu, Zhang Ruili. Neurosyphilis: current research status and management strategy exploration [J]. Chinese Journal of Dermatology, 2021, 54(11): 951-954.
[11]	Jiao Qingqing, Zhang Xiaoyan, Ji Jiang. Biological indicators related to disease activity of chronic spontaneous urticaria: an update [J]. Chinese Journal of Dermatology, 2021, 0(1): 20201158-e20201158.
[12]	Gao Meng, Jiang Yiqun. Cutaneous manifestations of COVID-19 [J]. Chinese Journal of Dermatology, 2021, 0(1): 20200509-e20200509.
[13]	Yu Miao, Zhang Jing, Chen Yudi, Liu Bo, Song Xiaoting, Liu Jing, Zhang Xue, Zhao Zuotao. Evaluation of reliability, validity and sensitivity of the Chinese version of pruritus-specific quality of life instrument [J]. Chinese Journal of Dermatology, 2020, 53(9): 698-703.
[14]	Miao YU Yu-Di CHEN Bo Liu Xiao-Ting SONG Zuotao. The Chinese version of the Urticaria Control Test and validation of its reliability and validity [J]. Chinese Journal of Dermatology, 2020, 53(7): 533-538.
[15]	Li Yan, Xu Wei, Gu Heng, Ju Mei, Duan Yiqun, Zeng Xianyu, Diao Qingchun, Ning Chunzhu, Li Linfeng. Acrivastine combined with loratadine in the treatment of chronic refractory urticaria: a multicenter, randomized controlled study [J]. Chinese Journal of Dermatology, 2020, 53(5): 319-323.

Scoring systems for chronic spontaneous urticaria in clinical research and practice

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［30］

Related Articles 15

Metrics

Comments

Recommended 10